Table 2.

Baseline and end‐of‐treatment values for hemoglobin A1c and fasting plasma glucose

Variable	All patients		BMI <23 kg/m2		BMI ≥23 to <25 kg/m2		BMI ≥25 to <28 kg/m2		BMI ≥28 kg/m2
	Placebo	Ipragliflozin	Placebo	Ipragliflozin	Placebo	Ipragliflozin	Placebo	Ipragliflozin	Placebo	Ipragliflozin
HbA1c (%)
n	321	508	93	113	74	113	80	144	74	138
Baseline	8.34 ± 0.716	8.32 ± 0.716	8.32 ± 0.679	8.26 ± 0.732	8.40 ± 0.855	8.35 ± 0.699	8.31 ± 0.677	8.28 ± 0.716	8.35 ± 0.661	8.39 ± 0.716
EOT	8.74 ± 1.164	7.53 ± 0.734	8.72 ± 12.83	7.53 ± 0.694	8.81 ± 1.151	7.52 ± 0.698	8.66 ± 1.105	7.54 ± 0.805	8.78 ± 1.099	7.53 ± 0.725
Change	0.40 ± 0.919	−0.79 ± 0.664	0.40 ± 1.041	−0.73 ± 0.627	0.41 ± 0.817	−0.82 ± 0.649	0.36 ± 0.859	−0.74 ± 0.694	0.43 ± 0.931	−0.85 ± 0.674
Difference (95% CI)	−1.17 (−1.281, −1.067)		−1.10 (−1.331, −0.869)		−1.25 (−1.462, −1.039)		−1.12 (−1.330, −0.912)		−1.24 (−1.456, −1.020)
P‐value	<0.001		<0.001		<0.001		<0.001		<0.001
FPG (mg/dL)
n	321	508	93	113	74	113	80	144	74	138
Baseline†	176.6 ± 34.85	173.1 ± 34.98	174.1 ± 36.08	171.8 ± 34.67	183.4 ± 37.67	174.1 ± 31.92	172.8 ± 32.23	174.9 ± 35.81	177.1 ± 32.72	171.4 ± 36.93
EOT	182.3 ± 41.38	138.4 ± 24.30	176.5 ± 45.79	137.8 ± 22.26	192.7 ± 44.75	140.3 ± 26.51	177.5 ± 34.63	137.8 ± 23.92	184.5 ± 37.08	138.1 ± 24.59
Change	6.1 ± 31.84	−34.6 ± 31.27	2.4 ± 32.07	−34.0 ± 31.67	9.4 ± 33.18	−33.8 ± 30.37	4.8 ± 31.24	−37.1 ± 29.61	8.8 ± 30.86	−33.3 ± 33.45
Difference (95% CI)†	−41.8 (−45.56, −38.09)		−36.9 (−44.73, −29.08)		−47.4 (−55.85, −38.97)		−39.7 (−46.21, −33.14)		−44.2 (−51.80, −36.64)
P‐value	<0.001		<0.001		<0.001		<0.001		<0.001

Values are presented as mean ± standard deviation. Baseline values were compared between the ipragliflozin and placebo groups within each body mass index (BMI) category using independent‐samples t‐tests (P > 0.05 for all baseline variables). ^†Adjusted mean difference between groups. CI, confidence interval; EOT, end‐of‐treatment; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c.